Symmetrical Pattern: Keratosis pilaris often appears in a symmetrical pattern, meaning that the bumps are typically distributed in the same areas on both sides of the body, such as on both upper arms or thighs
The variability suggests individual factors heavily influence this outcome
de Oliveira B, Oliveira BC, Deutsch G, Pessanha FS, Thire R, de Castilho SR
In addition, the recent identification of the presence of shared genomic abnormalities between some melanomas and associated nevi has provided support for a potential role of some nevi ( - Pathway 1: the vast majority of acquired nevi possess single driver mutations of either BRAF V600E or NRAS Q61R/L ( - Pathway 4: some Spitz nevi harbor HRAS mutation or translocations with kinase gene fusions involving ALK , ROS , RET , MET , and NTRK ( - Pathway 7: NRAS mutation is most frequently observed in congenital melanocytic nevi ( - Pathway 8: some blue nevi harbor the GNAQ or GNA11 mutation ( In contrast to melanomas, which acquire additional driver mutations, nevi usually enter a suppressive state of replicative senescence which is regulated by the tumor suppressor gene CDKN2A via its proteins, p14 and p16, and various transcriptional controls of the cell cycle ( in situ ) as well as papulonodular tumorigenic dermal proliferations (melanocytomas), and both categories are subclassified into low-grade and high-grade ( BRAF or NRAS ( TERT promoter and, sometimes, hemizygous loss of CDKN2A are involved in the morphological progression to a classical (superficial spreading) melanoma in situ ( Many melanocytomas are instead dermal-based, thick, combined melanocytic tumors in which an activating mutation of BRAF (or, much less commonly, NRAS ) is followed by a second genetic hit with expansion of a morphologically peculiar (non-classical) clone of melanocytes
Accredited testing partner Identity and purity confirmed by MZ Biolabs (Tucson, AZ), a US DEA-licensed analytical facility, via HPLC purity analysis and mass-spectrometry identity confirmation under GLP standards
